ATE325187T1 - Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren - Google Patents

Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren

Info

Publication number
ATE325187T1
ATE325187T1 AT94919349T AT94919349T ATE325187T1 AT E325187 T1 ATE325187 T1 AT E325187T1 AT 94919349 T AT94919349 T AT 94919349T AT 94919349 T AT94919349 T AT 94919349T AT E325187 T1 ATE325187 T1 AT E325187T1
Authority
AT
Austria
Prior art keywords
vectors
retroviral
cells
present application
cell line
Prior art date
Application number
AT94919349T
Other languages
English (en)
Inventor
Jane C Burns
Jiing-Kuan Yee
Theodore Friedmann
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE325187T1 publication Critical patent/ATE325187T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
  • Inert Electrodes (AREA)
  • Road Paving Structures (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Traffic Control Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94919349T 1993-06-04 1994-06-03 Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren ATE325187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7320993A 1993-06-04 1993-06-04
US08/104,804 US5512421A (en) 1991-02-19 1993-08-10 Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors

Publications (1)

Publication Number Publication Date
ATE325187T1 true ATE325187T1 (de) 2006-06-15

Family

ID=26754237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919349T ATE325187T1 (de) 1993-06-04 1994-06-03 Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren

Country Status (7)

Country Link
US (2) US5512421A (de)
EP (1) EP0702717B1 (de)
JP (1) JP3655307B2 (de)
AT (1) ATE325187T1 (de)
AU (1) AU686181B2 (de)
DE (1) DE69434724T2 (de)
WO (1) WO1994029440A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0746625B1 (de) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
CA2194488A1 (en) * 1994-08-05 1996-02-15 Tod Paul Holler Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
EP0796331A2 (de) * 1994-12-30 1997-09-24 Chiron Corporation Produktion und darreichung von grossen rangen an rekombinanten retroviren
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
US5770720A (en) * 1995-08-30 1998-06-23 Barnes-Jewish Hospital Ubiquitin conjugating enzymes having transcriptional repressor activity
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
CA2237000A1 (en) * 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
EP0870050B1 (de) * 1995-12-29 2002-06-19 Chiron Corporation Toxisches protein exprimierende viren und produktionszellinien
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
FR2747046B1 (fr) * 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
JPH1080274A (ja) * 1996-09-06 1998-03-31 Hirofumi Hamada 核移行シグナルを結合したテトラサイクリン・トランスアクチベーター
US6818209B1 (en) * 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
GB2337520B (en) * 1998-05-22 2000-06-14 Oxford Biomedica Ltd Delivery system
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
ATE331030T1 (de) * 1996-11-04 2006-07-15 Ottawa Health Research Inst Verfahren zur expression von polypeptide in fishen durch wässerung in dns enthaltende lösung
CN1059599C (zh) * 1996-12-27 2000-12-20 中国科学院水生生物研究所 蛙病毒疫苗
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
EP2008664B1 (de) * 1997-04-10 2012-08-29 University Of Southern California Modifizierte Proteine zur Bindung extrazellulärer Matrixkomponenten
AU2560999A (en) * 1998-01-21 1999-08-09 Regents Of The University Of Michigan, The Targeting gene transfer vectors to certain cell types by pseudotyping with viralglycoprotein
US6171862B1 (en) 1998-03-31 2001-01-09 The Regents Of The University Of California Transfection in serum-containing media
US20060292121A1 (en) * 1998-04-29 2006-12-28 Hall Frederick L Retroviral vectors including modified envelope escort protein
US7078483B2 (en) * 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
US7033595B1 (en) 1998-08-04 2006-04-25 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
WO2000008131A2 (en) * 1998-08-04 2000-02-17 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
GB9904905D0 (en) * 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
CA2371216A1 (en) * 1999-04-23 2000-11-02 Centre For Translational Research In Cancer Pseudotyped retroviral vector for gene therapy of cancer
ATE367445T1 (de) * 1999-05-18 2007-08-15 Dnavec Research Inc Viraler paramyxoviridae vektor mit einem defekten hüllprotein-gen
US6518481B1 (en) * 1999-08-12 2003-02-11 Exelixis, Inc. Universal markers of transgenesis
CA2413156C (en) * 2000-07-03 2009-08-18 Gala Design, Inc. Expression vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
JP2002176880A (ja) * 2000-12-12 2002-06-25 Kanegafuchi Chem Ind Co Ltd 効率的な遺伝子導入鳥類の作製法及びそれによって得られる遺伝子導入鳥類
US7141649B2 (en) * 2001-01-26 2006-11-28 Vanderbilt University Mosquito arrestin 2 polypeptides
US7314723B2 (en) * 2001-01-26 2008-01-01 Vanderbilt University Method of identifying chemical agents which stimulate odorant receptors of sensory neurons
US7166699B2 (en) * 2001-01-26 2007-01-23 Vanderbilt University Mosquito arrestin 1 polypeptides
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
AU2002343901A1 (en) 2001-09-29 2003-04-14 Kim, Joo-Hang Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US7981656B2 (en) * 2002-06-04 2011-07-19 Purdue Research Foundation Pseudotyped retrovirus with modified ebola glycoprotein
JP2005537802A (ja) * 2002-09-09 2005-12-15 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション ラブドウイルスの組み換え型変異体及びその使用方法
ES2366617T3 (es) * 2003-04-21 2011-10-21 Epeius Biotechnologies Corporation Métodos y composiciones para el tratamiento de transtornos.
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ATE488252T1 (de) * 2003-05-05 2010-12-15 Virxsys Corp Erhöhte transduktion mit abc- transportersubstratenhemmern
SI1629004T1 (sl) * 2003-06-05 2008-12-31 Wyeth Corp Imunogeni sestavki, ki vsebujejo vektorski replikon virusa venezuelskega konjskega encefalitisa in antigen za protein paramiksovirusa
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
WO2005038035A2 (en) * 2003-10-15 2005-04-28 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses
JP4588639B2 (ja) * 2003-11-17 2010-12-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ｈＥＲＧチャネル発現細胞
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
JP5546716B2 (ja) 2004-09-29 2014-07-09 タカラバイオ株式会社 レトロウイルスベクター産生用細胞
WO2006127585A2 (en) * 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
US8685720B2 (en) * 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
DE102006061184A1 (de) 2006-12-22 2008-06-26 Fresenius Medical Care Deutschland Gmbh Verfahren zum Primen eines Blutschlauchsatzes
WO2010105020A2 (en) * 2009-03-13 2010-09-16 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8961951B2 (en) * 2007-07-06 2015-02-24 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
JP2011517409A (ja) * 2008-03-28 2011-06-09 バイレクシス コーポレイション レンチウイルスベースの免疫原性ベクター
US20100076061A1 (en) * 2008-04-30 2010-03-25 University Of Iowa Research Foundation Repeated administration of lentiviral vectors to respiratory cells
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
JP5965392B2 (ja) 2010-05-28 2016-08-03 オックスフォード バイオメディカ （ユーケー） リミテッド 脳へのレンチウイルスベクターの送達
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
CN105283553B (zh) 2013-06-11 2021-06-25 克隆技术实验室有限公司 蛋白质富集的微泡及其制备和使用方法
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
EP3313420B1 (de) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Verfahren und zusammensetzungen in bezug auf hämatopoetische stammzellenexpansion, -anreicherung und -pflege
EP3426353A4 (de) 2016-03-09 2020-05-06 The University of Massachusetts Verwendung von modifiziertem hiv-1 zur erzeugung von vollständig humanen antikörpern
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
AU2018253115B2 (en) 2017-04-12 2022-08-11 Edigene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
JP7412341B2 (ja) 2017-10-31 2024-01-12 エディジーン バイオテクノロジー インコーポレイテッド 造血幹細胞および前駆細胞の増幅のための組成物および方法
US20190343885A1 (en) 2017-10-31 2019-11-14 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3696272A1 (de) 2017-12-22 2020-08-19 Oxford BioMedica (UK) Limited Retroviraler vektor
AU2019205262A1 (en) 2018-01-03 2020-07-23 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
KR20210071976A (ko) 2018-09-04 2021-06-16 마젠타 테라퓨틱스 인코포레이티드 아릴 하이드로카본 수용체 길항제 및 사용 방법
WO2020117910A1 (en) 2018-12-04 2020-06-11 Catalent Pharma Solutions, Llc Vectors for protein manufacture
CA3133188A1 (en) 2019-03-10 2020-09-17 Oxford Biomedica (Uk) Limited Gene therapy compositions and methods for treating parkinson's disease
KR20220097492A (ko) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
JP2023513303A (ja) 2020-02-13 2023-03-30 オックスフォード バイオメディカ（ユーケー）リミテッド レンチウイルスベクターの製造
US20230118587A1 (en) 2020-03-13 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral Vectors
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
FR2619012B1 (fr) * 1987-08-07 1989-12-22 Pasteur Institut Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus
CA2002839C (en) * 1988-11-14 2000-10-10 Neal S. Young Parvovirus capsids
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
EP1288304A3 (de) * 1989-06-01 2006-04-05 Applied Biotechnology, Inc. Selbstzusammengesetzte, Defekte, sich Nichtselbstvermehrende
EP0487587A1 (de) * 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
EP0897987B1 (de) * 1989-10-24 2001-02-28 Chiron Corporation Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
DE69131908T3 (de) * 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum

Also Published As

Publication number Publication date
DE69434724T2 (de) 2007-05-10
EP0702717A1 (de) 1996-03-27
JP3655307B2 (ja) 2005-06-02
JPH08511685A (ja) 1996-12-10
AU7052394A (en) 1995-01-03
DE69434724D1 (de) 2006-06-08
US5670354A (en) 1997-09-23
WO1994029440A1 (en) 1994-12-22
US5512421A (en) 1996-04-30
AU686181B2 (en) 1998-02-05
EP0702717B1 (de) 2006-05-03
EP0702717A4 (de) 2000-04-05

Similar Documents

Publication Publication Date Title
DE69434724D1 (de) Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren
DE59911900D1 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
CA2104396A1 (en) Viral particles having altered host range
NZ269019A (en) Method of inducing transduction with retroviral assistance
ATE67244T1 (de) Herstellung und reinigung von lymphokinen.
ATE147758T1 (de) Von synthetischer dns abgeleitete rekombinante hiv-1-antigene
CA2410297A1 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
DE69125925D1 (de) Rekombinante herpes simplex virus impfstoffe und methoden
IL123833A0 (en) Vector and method of use for nucleic acid delivery to non-dividing cells
DE69129927D1 (de) G-CSF polypeptide derivatives
DK355486A (da) Fusionsproteiner, deres fremstilling og anvendelse
DE69311427D1 (de) Synthetische Polypeptide als Inhibitoren von HIV-1
PT100245A (pt) Sequencia de adn que codifica um derivado de factor viii humano recombinante, biologicamente activo, vector de expressao recombinante, celula hospedeira, processo de producao de um derivado de factor vii e derivado de factor viii
DK192189D0 (da) Polypeptid, fremgangsmaade til inhibering af fibrinogen, fremgangsmaade til rensning af et polypeptid, gen indeholdende rekombinante dna kodende for et polypeptid, vektor, cellekultur og fremgangsmaade til fremstilling af et cysteinrigt polypeptid
JPH09289896A5 (de)
DK0386752T3 (da) Polypeptid og fremstilling heraf
Suarez et al. Identification of hypervariable and conserved regions in the surface envelope gene in the bovine lentivirus
CA2164324A1 (en) Generation concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
DE69318716D1 (de) Anti-Katze Immundefiziensvirus (FIV) Impfstoffe
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
Hantula et al. Chemical crosslinking of bacteriophage φ6 nucleocapsid proteins
York et al. Some characteristics of a retrovirus isolated from transformed bovine cells
JPS642581A (en) Dna capable of coding rinderpest virus antigenic protein
Jupp et al. Substrate cleavage by HIV-1 proteinase
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties